Avidity Biosciences - RNA Competitors

Travere Therapeutics (NASDAQ:TVTX) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Does the media prefer TVTX or RNA?

In the previous week, Avidity Biosciences had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Avidity Biosciences and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.11 beat Avidity Biosciences' score of 0.11 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is TVTX or RNA more profitable?

Travere Therapeutics has a net margin of -131.35% compared to Avidity Biosciences' net margin of -1,886.33%. Avidity Biosciences' return on equity of -40.82% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-131.35%	-219.11%	-37.05%
Avidity Biosciences	-1,886.33%	-40.82%	-36.41%

Which has preferable earnings and valuation, TVTX or RNA?

Avidity Biosciences has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$212.02 million	6.87	-$278.48 million	-$4.37	-5.15
Avidity Biosciences	$9.22 million	117.89	-$173.99 million	-$3.33	-4.61

Do analysts rate TVTX or RNA?

Travere Therapeutics currently has a consensus price target of $32.91, indicating a potential upside of 46.33%. Avidity Biosciences has a consensus price target of $43.60, indicating a potential upside of 184.04%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Does the MarketBeat Community prefer TVTX or RNA?

Avidity Biosciences received 90 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 63.45% of users gave Avidity Biosciences an outperform vote while only 49.30% of users gave Travere Therapeutics an outperform vote.

Company	Underperform	Outperform
Travere Therapeutics	Outperform Votes 35 49.30%	Underperform Votes 36 50.70%
Avidity Biosciences	Outperform Votes 125 63.45%	Underperform Votes 72 36.55%

Summary

Avidity Biosciences beats Travere Therapeutics on 12 of the 16 factors compared between the two stocks.